For the treatment of adults

with community-acquired

bacterial pneumonia

The Total
CABP Package

XENLETA: A CABP-targeted spectrum of coverage for the right patient in just 5 days.

Demonstrated monotherapy efficacy

XENLETA achieved early and effective clinical response against common CABP pathogens in as short as 5 total days of therapy.1

See the results

XENLETA has a low risk of resistance and cross-resistance due to novel MOA

The first and only oral pleuromutilin antibiotic that may remain active against clinical isolates resistant to other treatments1

Get the details

Appropriate treatment for patients most at risk of negative outcomes
with CABP

Explore our patient profiles to see case studies illustrating when to consider XENLETA and how it may help patients like yours.

See the profiles

Discuss XENLETA in person

Request a visit from a sales representative to learn more about XENLETA. Your sales rep can also provide sample packs.

Request a rep/sample pack